Psychiatr. pro Praxi, 2004; 6: 297-302 [Interní Med. 2004; 6(8): 403-409]

Stárnutí ženy a hormonální substituční terapie

prof. MUDr. Jaroslav Živný DrSc
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze

Keywords: aging of a woman, menopause, climacterium, climacteric syndrome, hormonal replacement therapy, oestrogen replacement therapy.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Živný J. Stárnutí ženy a hormonální substituční terapie. Psychiatr. praxi. 2004;9(6):297-302.

Klimakterium je období přechodu mezi reprodukčním obdobím a seniem, ve kterém postupně zaniká funkce vaječníku. Je podán přehled současných názorů na endokrinologii procesu stárnutí u ženy, na změny probíhající v jednotlivých orgánech event. systémech, na farmakologii, indikace a kontraindikace hormonální substituční terapie. Ženám s dělohou podáváme kombinaci estrogenů s progestiny (HST), ženám bez dělohy pouze estrogeny (EST). HST/EST musí být indikovaná a přísně individuální. Je stále nejlepším lékem pro akutní klimakterický syndrom a pro prevenci a léčbu atrofie urogenitálního traktu. Diskutována je otázka významu, přínosu a rizika v prevenci a léčbě osteoporózy.

Aging of a woman and hormonal replacement therapy

Climacterium (= change of life) is period between a reproduction and oldness, when a function of ovary fades slowly. Overview on contemporary opinions on endocrinology of this process of aging of a woman is presented, on undergoing changes in single organs or systems, on pharmacology, indications and contraindications of hormonal replacement therapy. Women with a uterus are given a combination of oestrogens and progestins (HRT), women without uterus oestrogens only (ERT). HRT/ERT must be indicated and strictly individual. It is still the best treatment for acute climacteric syndrome and for prevention and treatment of genitourinary tract atrophy. The questions on importance, profit and a risk in prevention and therapy of osteoporosis are discussed.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cibula D, Henzl MR, Živný J, et al: Základy gynekologické endokrinologie, Grada Avicenum Praha 2002, 344 s.
    2. Cushman M, Legault C, Barrett-Connor E, et al: Effect of postmenopausal hormones on inflammation-sensitive proteins: the postmenopausal European/Progestin Interventions (PEPI) Study. Circulation 1999: 100, s. 717. Go to original source... Go to PubMed...
    3. Donát J: Estrogenní deficit v klinické praxi, DoMeNa Praha 2003, 184 s.
    4. Hormone replacement therapy and the menopause, Marsh MS and Compston JE (ed)., M. Dunitz Ltd, London 2002.
    5. Hulley S, Furberg C, Barrett-Connor E, et al Nonvascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin replacement Study follow - up (HERS II) JAMA 1999; 6: 147.
    6. Hulley S, Grady D, Bush T, et al: for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial for estrogenplus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605. Go to original source... Go to PubMed...
    7. Grady D, Herrington D, Bittner V, et al: Cardiovascular diseases outcomes during 6.8 years of hormone therapy: Heart et Estrogen/progestin Replacement Study follow up (HERS II). JAMA 2002; 288: 49. Go to original source... Go to PubMed...
    8. Lobo RA. Homocystein i women´s health Menopause 2003; 10: 271.
    9. Menopause. The State of Art, HPG Schneider (ed). The Parthenon Publishing Group.Boca Raton-London-New York-Washington DC 2003.
    10. Million Women Study Collaborators. Brest Cancer and hormone replacement therapy in the Million Women Study Lancet 2003; 362: 419. Go to original source... Go to PubMed...
    11. NAMS Report: Amended report from the NAMS advisory panel on postmenopausal hormone terapy. Menopause 2003; 10: 6-12. Go to original source... Go to PubMed...
    12. The North American Menopausal Society Report: Amended report from the NAMS advisory panel on postmenopausal hormone terapy. Menopause 2003; 10: 6. Go to original source... Go to PubMed...
    13. Rapp SR, Espeland MA, Shumaker SA. Effect of estrogen prus progestin on gobal cognitive function in postmenopausal women. The Women´s Health Initiative Memory Study: A randomized controlled trial JAMA 2003; 289: 2663. Go to original source... Go to PubMed...
    14. Scarabin PY, Oger E, Plu-Bureau G. for Estrogen ThromboEmbolism Risk (ESTHER) Study Group. Differential association of oral and transdermal estrogen-replacement therapy with venous thromboembolism risk Lancet 2003; 362: 428. Go to original source... Go to PubMed...
    15. Schindler AE. Hormone replacement therapy (HRT) after genital cancer Maturitas 2002; 41 (suppl 1): 105. Go to original source... Go to PubMed...
    16. Shumaker SA, Legault C, Rapp SR. Estrogen plus progestin and the incidence of dementia and Mild cognitive impairment in postmenopausal women. The Women´s Health Initiative Memory Study: A randomized controlled trial JAMA 2003; 289: 2651. Go to original source... Go to PubMed...
    17. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant supplements on coronary arteriosclerosis in postmenopausal women: randomized controlled trial JAMA 2002; 288: 2432. Go to original source... Go to PubMed...
    18. Writing Group for the Women´s Health Initiative Investigators: Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women´s Health Initiative randomized trial JAMA 2002; 288: 321. Go to original source... Go to PubMed...
    19. Živný J, Jeníček J, Fait T, et al. Changes in bone density and bone metabolism in women with chirurgically induced manopause treated with hormone replacement therapy drug containing estradiol valerate andlevonorgestrel Drugs of Dday 2001; 37 (suppl C): 37.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.